Primary renal neuroendocrine tumor combined with horseshoe kidney: a case report and review of the literature Authors: Jiaxuan Ni, Shang Wu, Xuefei Ding, Guangchen Zhou Published: 2025 ABSTRACT BackgroundPrimary renal neuroendocrine tumors (PRNETs) are exceptionally rare neoplasms, with only limited cases documented in the literature. Their occurrence in association with horseshoe kidney represents an even rarer clinical scenario. This report presents a case of well-differentiated neuroendocrine tumor arising in a horseshoe kidney and discusses its clinical management and prognostic implications.Case presentationA 58-year-old female was admitted after an incidental discovery of a left renal mass during a routine health examination. Imaging studies, including enhanced CT and MRI, revealed a horseshoe kidney with a 5.5 × 4.7 cm cystic-solid mass in the mid-lower portion of the left kidney, classified as Bosniak IV. The patient underwent laparoscopic partial nephrectomy via a retroperitoneal approach. Histopathological and immunohistochemical analyses confirmed a well-differentiated neuroendocrine tumor, with positive staining for Syn, CD56, SSTR2, and focal CgA, and a low Ki67 index (3%). The postoperative course was uneventful, and no recurrence or metastasis was observed during the 12-month follow-up.ConclusionPRNETs, though rare, should be considered in the differential diagnosis of renal masses, particularly in patients with congenital renal abnormalities such as horseshoe kidney. Nephron-sparing surgery may be a feasible option in selected cases, with favorable short-term outcomes. Long-term follow-up is essential due to the potential for delayed metastasis. Immunohistochemical profiling plays a critical role in diagnosis and therapeutic planning, especially regarding the potential use of somatostatin analogs.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12894-025-02020-1. Background Neuroendocrine neoplasms arise from the diffuse neuroendocrine cell system and are most frequently found in the digestive and respiratory tracts, including the stomach, intestines, and lungs [1]. These neoplasms may develop from hormone-secreting cells capable of producing substances such as serotonin, insulin, gastrin, and insulin-like growth factors [1]. Owing to their hybrid neural and endocrine characteristics, these lesions are classified as neuroendocrine neoplasms [1]. According to the World Health Organization, renal neuroendocrine neoplasms are categorized into four types” well-differentiated neuroendocrine tumor (NET), neuroendocrine carcinomas (NEC) (large cell and small cell), and paragangliomas (pheochromocytoma is not acceptable) [2]. Primary renal neuroendocrine tumor (PRNET) represents a comparatively rare subtype. Although evidence remains limited, several case reports and small-scale studies have been published in recent years, including a single-center study of 17 patients [3]. Since neuroendocrine cells are not typically present in the kidney, it is hypothesized that PRNETs may originate from pluripotent stem cells undergoing aberrant neuroendocrine differentiation [4]. PRNETs are generally associated with a poor prognosis, albeit with significant individual variation [2]. Herein, we report a case of a 58-year-old woman diagnosed with a primary renal neuroendocrine tumor in conjunction with a horseshoe kidney. Case presentation A 58-year-old female was admitted to the hospital due to “a space-occupying lesion in the left kidney found during health checkup two weeks prior.” She reported no symptoms such as lumbar pain, urinary frequency, dysuria, incomplete voiding, painful urination, hematuria, or fever. There were no respiratory symptoms such as cough, sputum, chest pain, or tightness, nor gastrointestinal symptoms such as abdominal pain, diarrhea, or changes in bowel habits. Enhanced computed tomography (CT) of the abdomen revealed a horseshoe kidney and a cystic-solid mass adjacent to the mid-lower portion of the left kidney, classified as Bosnisk category IV (Fig. 1). Magnetic resonance imaging (MRI) of the abdomen confirmed a space-occupying lesion (5.5 × 4.7 cm) in the left kidney along with a horseshoe kidney (Fig. 2); Renal function tests showed creatinine 77 µmol/L and urea 3.92 mmol/L. The R.E.N.A.L. nephrometry score was R2 E1 N3 A L3. Preoperative chest CT showed no significant abnormalities. After discussing treatment options with the patient, who expressed a strong desire for kidney preservation, laparoscopic partial nephrectomy was performed via a retroperitoneal approach. During surgery, a well-encapsulated cystic-solid mass approximately 5.0 cm in diameter was identified in the mid-lower portion of the left kidney. The renal artery was clamped, and the mass was completely excised within approximately 20 min of ischemia time. The resection surface was covered with hemostatic gauze. The patient recovered well postoperatively, with the drainage tube removed on day 6 and discharge on day 7. No significant surgical complications occurred. Fig. 1Enhanced CT: the inferior poles of both kidneys are fused. Adjacent to the mid-inferior aspect of the left kidney, a predominantly hypodense lesion projecting into the renal sinus is observed. The lesion exhibits heterogeneous attenuation with patchy areas of mild hyperdensity and punctate enhancement. Fine internal septations are present. Focal fusiform thickening of the wall is seen protruding into the lumen, with partial extension beyond the cystic contour. During the triple-phase enhancement, the thickened wall and the extracapsular nodular component demonstrate similar attenuation values, measuring approximately 70–80 HU Enhanced CT: the inferior poles of both kidneys are fused. Adjacent to the mid-inferior aspect of the left kidney, a predominantly hypodense lesion projecting into the renal sinus is observed. The lesion exhibits heterogeneous attenuation with patchy areas of mild hyperdensity and punctate enhancement. Fine internal septations are present. Focal fusiform thickening of the wall is seen protruding into the lumen, with partial extension beyond the cystic contour. During the triple-phase enhancement, the thickened wall and the extracapsular nodular component demonstrate similar attenuation values, measuring approximately 70–80 HU Fig. 2MRI (A) T2-weighted image (B) diffusion weighted imagining (C) apparent diffusion coefficient mapping: The inferior poles of both kidneys are fused. A round-like mass, measuring approximately 55 mm × 47 mm, is identified in the left kidney, demonstrating slightly short T1 and slightly long T2 signals. The lesion exhibits heterogeneously increased signal on DWI. The posterior margin is poorly demarcated from the renal parenchyma with a cup-shaped indentation. Mass effect is evident, resulting in compression and dilation of the left renal pelvis MRI (A) T2-weighted image (B) diffusion weighted imagining (C) apparent diffusion coefficient mapping: The inferior poles of both kidneys are fused. A round-like mass, measuring approximately 55 mm × 47 mm, is identified in the left kidney, demonstrating slightly short T1 and slightly long T2 signals. The lesion exhibits heterogeneously increased signal on DWI. The posterior margin is poorly demarcated from the renal parenchyma with a cup-shaped indentation. Mass effect is evident, resulting in compression and dilation of the left renal pelvis Histopathological examination of the specimen revealed a tissue mass measuring 6 × 5 × 2.5 cm. Macroscopically, the lesion was mostly cystic with a wall thickness of 0.1–0.4 cm; the cut surface was gray-white and of medium firmness. A nodule measuring 1.6 × 1.5 × 1.5 cm was observed on the cystic wall, which was cystic itself and contained yellow material. Microscopically, hematoxylin and eosin (H&E) staining showed that the cystic wall was composed of fibrous tissue, largely devoid of epithelial lining, though focal areas were covered by urothelium. Tumor cells within the cystic wall were arranged in trabecular, ribbon-like, and nested patterns (Fig. 3A). The cells were uniform in size and shape, with round nuclei, and no significant necrosis was observed. Immunohistochemical results were as follows: CKpan (+), CD56 (+) (Fig. 3B), CgA (focal +) (Fig. 3C), Syn (+) (Fig. 3D), GATA-3 (–), Ki67 (approximately 3% positive in hot spots), PAX-8 (–), and SSTR2 (+). Based on H&E and immunohistochemical findings, the diagnosis was well-differentiated neuroendocrine tumor with extensive cystic degeneration and a focal dermoid cyst component. Notably, no other teratomatous components (e.g., ectodermal tissues like squamous epithelium or skin appendages, or mesodermal tissues like cartilage or smooth muscle) were identified upon thorough histological examination of the entire specimen. The patient underwent follow-up chest X-ray and abdominal CT every three months after discharge. No recurrence or metastasis was observed within one year post-surgery. During follow-up, the patient did not exhibit any symptoms of carcinoid syndrome, such as flushing, wheezing, abdominal pain, or diarrhea. Fig. 3Photomicrographs showing histological and immunohistochemical features: A. H&E staining; B. CD56-positive immunohistochemical staining; C. Chromogranin A (CgA) with focal positivity; D. Synaptophysin (Syn)-positive immunohistochemical staining Photomicrographs showing histological and immunohistochemical features: A. H&E staining; B. CD56-positive immunohistochemical staining; C. Chromogranin A (CgA) with focal positivity; D. Synaptophysin (Syn)-positive immunohistochemical staining Discussion Pathogenesis Neuroendocrine neoplasms are generally rare, with most cases occurring in the gastrointestinal tract and lungs; involvement of the urinary system is uncommon and typically affects organs such as the testis and prostate [4]. In this case, preoperative chest CT, abdominal enhanced CT, and MRI showed no suspicious related lesions, supporting the diagnosis of primary tumor. PRNET accounts for less than 0.4% of all neuroendocrine neoplasms [5]. The pathophysiology of NETs remains incompletely understood. As neuroendocrine cells are not normally present in the kidney, some researchers suggest that these tumors may arise from aberrant activation of genetic sequences in pluripotent stem cells with potential for neuroendocrine differentiation [4]. Other proposed mechanisms include metaplasia of the renal pelvic urothelium due to chronic inflammation, metastasis from an occult primary tumor, or misplacement of neural crest or pancreatic tissue during embryonic development [5]. A coexistence hypothesis has also been proposed, suggesting that proliferation of scattered endocrine cells may originate from the epithelium of a horseshoe kidney or polycystic kidney [6, 7]. Previous studies have indicated that the risk of neuroendocrine neoplasms is 62–82 times higher in patients with horseshoe kidney compared to those with normal renal anatomy [8]. Horseshoe kidney is a congenital renal fusion anomaly that is more common in males [9]. One-third of affected individuals remain asymptomatic until adulthood [10]. However, horseshoe kidney is frequently associated with renal and extrarenal complications, including ureteropelvic junction obstruction, urinary tract infections, lithiasis, and tumors—though renal tumors in such cases are rare [11]. Clinical manifestations PRNETs often lack characteristic clinical presentations and are mostly detected incidentally during physical examination. Reported symptoms may include lumbar pain, abdominal distension, a palpable mass, hematuria, and occasionally carcinoid syndrome (e.g., diarrhea, facial flushing, dyspnea), Cushing’s syndrome, or Verner–Morrison syndrome [12, 13]. Patients with renal paragangliomas may present with symptoms related to epinephrine excess, such as back pain, headache, and tachycardia. The absence of obvious symptoms in this patient is consistent with findings from other studies. Auxiliary examinations Most PRNETs are discovered incidentally during routine clinical imaging such as CT or MRI. However, imaging features are non-specific and often indistinguishable from other renal tumors. CT typically shows a well-defined mass with mild to moderate enhancement, solid components, and occasional cystic changes or calcifications. MRI often reveals heterogeneous signal intensity on both T1- and T2-weighted images [14]. 18 F-fluorodeoxyglucose (18 F-FDG) PET/CT can also be used for localization, particularly in cases of sympathetic paragangliomas, multifocal or malignant pheochromocytomas. Additionally, genetic sequencing may help improve diagnostic accuracy. Grading Although there is no established grading system specifically for renal NETs, the current WHO guidelines recommend using the grading system for gastrointestinal and pancreatic NETs [15]. The grading system based on proliferation assessed by mitotic rate and Ki67 labeling index stratifies NETs into grade 1 (G1), grade 2 (G2), or grade 3 (G3), corresponding to low-grade, intermediate-grade, and high-grade categories [16, 17] (Table 1). Table 1The world health organization (WHO) 2022 grading system for Gastrointestinal and pancreatic neuroendocrine neoplasmsNeuroendocrine neoplasmClassificationClassificationWell-differentiated neuroendocrine tumor(NET)NET, grade 1< 2 mitoses/2 mm2and/or Ki67 < 3%NET, grade 22–20 mitoses/2 mm2and/or Ki67 > 3–20%NET, grade 3> 20 mitoses/2 mm2and/or Ki67 > 20%Poorly differentiated neuroendocrine carcinoma(NEC)Small cell NEC> 20 mitoses/2 mm2and/or Ki67 > 20%(often > 70%), and small cell cytomorphologyLarge cell NEC> 20 mitoses/2 mm2and/or Ki67 > 20%(often > 70%), and large cell cytomorphology Table 1The world health organization (WHO) 2022 grading system for Gastrointestinal and pancreatic neuroendocrine neoplasmsNeuroendocrine neoplasmClassificationClassificationWell-differentiated neuroendocrine tumor(NET)NET, grade 1< 2 mitoses/2 mm2and/or Ki67 < 3%NET, grade 22–20 mitoses/2 mm2and/or Ki67 > 3–20%NET, grade 3> 20 mitoses/2 mm2and/or Ki67 > 20%Poorly differentiated neuroendocrine carcinoma(NEC)Small cell NEC> 20 mitoses/2 mm2and/or Ki67 > 20%(often > 70%), and small cell cytomorphologyLarge cell NEC> 20 mitoses/2 mm2and/or Ki67 > 20%(often > 70%), and large cell cytomorphology The world health organization (WHO) 2022 grading system for Gastrointestinal and pancreatic neuroendocrine neoplasms Well-differentiated neuroendocrine tumor (NET) < 2 mitoses/2 mm2 and/or Ki67 < 3% 2–20 mitoses/2 mm2 and/or Ki67 > 3–20% > 20 mitoses/2 mm2 and/or Ki67 > 20% Poorly differentiated neuroendocrine carcinoma (NEC) > 20 mitoses/2 mm2 and/or Ki67 > 20% (often > 70%), and small cell cytomorphology > 20 mitoses/2 mm2 and/or Ki67 > 20% (often > 70%), and large cell cytomorphology Pathological features Definitive diagnosis of PRNET relies on pathological examination and immunohistochemical analysis. Most PRNETs present as well-circumscribed solid masses with a gray-white or tan cut surface; hemorrhage and necrosis are uncommon [14, 18]. Tumor cells are typically round or polygonal, arranged in trabecular or ribbon-like patterns, with eosinophilic cytoplasm, basophilic nuclei, fine chromatin, inconspicuous nucleoli, and rare necrosis [19]. Immunohistochemistry is crucial for diagnosis and differential evaluation. PRNETs typically express neuroendocrine markers such as NSE, CgA, Syn, and CD56. Among these, NSE is sensitive but not specific, while CgA is specific but less sensitive. CgA levels can be influenced by various conditions, including other tumors and non-neoplastic diseases [4]. Ki67 is a reliable pathological marker for determining tumor grade [15]. According to Ki67 index and mitotic count, NETs can be divided into G1, G2 and G3. INSM1 (Insulinoma-associated protein 1) has also emerged as a highly sensitive and specific nuclear marker for neuroendocrine differentiation across various neuroendocrine neoplasms and can be a valuable addition to the diagnostic panel [15]. The vast majority of neuroendocrine tumors show positivity for at least one neuroendocrine marker. In this case, the tumor cells exhibited trabecular, ribbon-like, and nested patterns, with uniform size and shape, round nuclei, and no significant necrosis. Immunohistochemically, the tumor cells were positive for CKpan, CD56, Syn, and SSTR2, focally positive for CgA, and negative for GATA-3 and PAX-8. The Ki67 index was low (approximately 3% in hot spots). CKpan positivity indicates epithelial origin, helping to rule out non-epithelial tumors such as lymphoma, melanoma, sarcoma, and paraganglioma. GATA-3 negativity helps exclude urothelial carcinoma (a common renal pelvic cancer) and some breast-derived tumors. PAX-8 negativity aids in ruling out renal cell carcinoma (the most common primary renal tumor) as well as tumors of ovarian or fallopian tube origin. CD56 is a highly sensitive (though non-specific) neuroendocrine marker, while CgA is relatively specific; Syn is both highly sensitive and reliable. The positivity for these three markers strongly supports a neuroendocrine origin. The low Ki67 index suggests low proliferative activity, indicating a low-grade tumor with indolent biological behavior, slow growth, and favorable prognosis. SSTR2 positivity is particularly significant, as it not only further supports the diagnosis of NET but also suggests that the tumor may be amenable to diagnostic (e.g., PET/CT imaging) and therapeutic applications of somatostatin analogs (such as octreotide). Treatment strategies For patients initially diagnosed with non-metastatic PRNET, some scholars recommend radical nephrectomy as the primary treatment option. The specific surgical approach should be determined based on comprehensive factors such as tumor size, location, and presence of metastasis. If lymph node enlargement is identified, concomitant lymph node dissection should be performed [4]. Patients undergoing radical nephrectomy generally exhibit a favorable prognosis. However, some may develop widespread metastatic disease even several years after surgery. There are literature reports of rare cases where distant metastasis occurred as long as seven years post-nephrectomy [20, 21]. Therefore, even with well-differentiated tumors or early-stage disease, follow-up examinations every three months are recommended [2]. For progressive disease, somatostatin analogs represent one of the effective pharmacological options for controlling tumor advancement [22]. Although the present case involved a well-differentiated neuroendocrine tumor, nephron-sparing surgery was performed instead of radical nephrectomy. Thus, postoperative management requires strict adherence to long-term follow-up protocols specific to renal neuroendocrine tumors, which is essential for further improving patient survival and quality of life. Prognosis PRNETs are generally of low malignancy and slow-growing, hence associated with a relatively favorable prognosis. Mitotic count and the degree of cellular atypia are closely related to patient outcomes [23]. Nevertheless, the precise prognostic implications of concurrent PRNET and horseshoe kidney have not been conclusively determined. Owing to the paucity of data, there are marked discrepancies in the findings reported by various institutions [4, 24]. Further research is needed to clarify prognostic factors and long-term outcomes. Conclusion In summary, well-differentiated primary renal neuroendocrine tumors are rare neoplasms with a favorable prognosis following nephron-sparing surgical resection. However, due to their rarity, current understanding and consensus regarding PRNET remain limited. Our case offers valuable insights that may assist clinicians in the diagnosis and management of this condition. Nonetheless, this study has certain limitations, and longer follow-up periods as well as larger sample sizes are warranted in future research. Supplementary Information Supplementary Material 1. Supplementary Material 1.